Trial Profile

Bendamustine,Pomalidomide and Dexamethasone in Relapsed and/or refractory Multiple Myeloma - BASiL

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bendamustine (Primary) ; Dexamethasone (Primary) ; Pomalidomide (Primary)
Indications Multiple myeloma
Focus Therapeutic Use
Acronyms BASiL

Most Recent Events

01 Jul 2022 Status changed from not yet recruiting to completed, according to Results published in the British Journal of Haematology.
01 Jul 2022 Results assessing role of bendamustine, pomalidomide and dexamethasone combination in this setting, published in the British Journal of Haematology.
18 Jun 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com